Bill E. Cham
Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers, 2007

Research Journal of Biological Sciences 2 (4): 503-514, 2007
Read Full Article

Excerpt:
BEC in a topical cream formulation is now available clinically for the treatment of non malignant and malignant human skin cancers. BEC is very selective in killing cancer cells without harming normal cells due to a unique mode of action. In addition BEC exerts its antineoplastic activity on cancer cells at proliferative as well as "resting" (nonproliferative) stages of their life cycles. BEC, due to its selectivity and efficacy is superior to other well established antineoplastics. The observations that BEC has good antineoplastic activities, together with a very high safety profile, have paved the way for much work currently being undertaken to establish the potential of BEC as a new antineoplastic agent for internal cancers.

Curaderm-BEC has Achieved Outstanding Clinical Success for over 20 years.

All research has been verified by independent scientists worldwide.

Clinical research and medical information over twenty years of medical evidence, including photographs of patient cases and other conclusive clinical data such as follow up tests for up to ten years assuring that no adverse reactions or skin cancer return/recurrence occurred published in prestigious medical journals such as Cancer Letters, Drugs of Today, Asian Journal of Pharmacology, Drugs of the Future, Medical Journal of Australia and many more.

United Kingdom Dermatologist Phase 3 Clinical Trials and Open Studies. U.K Hospitals, 2002

The general success rate of the glycoalkaloid (BEC) cream was 78 percent. Longer duration therapy with BEC would have resulted in higher success rates. These results were comparable to those previously obtained with Curaderm. Not only was it shown that this cream was effective in treating superficial BCC, but in a subsequent open study trial carried out at the Dermatology Department at the Royal London Hospital it was also shown that the glycoalkaloid cream was effective on morpheoic BCC lesions, which are a type of invasive BCC. The clinical trial experience has shown that the BEC was safe.
Read More

Cancer Letters, the World Authority on Cancer Research Recognises Curaderm-BEC5

Cancer Letters has published positive articles on Curaderm in 1987 and 1990 showing BEC’s breakthrough capacity to select between healthy cells and cancerous cells. “Furthermore, these results provide evidence that BEC selectively destroys tumor cells relative to normal cells”

Cancer Letters is an international journal providing a forum for original and pertinent contributions in cancer research.

Solasodine glycosides as Anti-cancer Agents. Pre-clinical and Clinical studies.
Asia Pacific Journal of Pharmacology, 1994

Solamargine a naturally occurring solasodine triglycoside binds to the EELs and this interaction initiates a chain of events, resulting in the internalisation of solamargine with concomitant delivery of solasodine to the targeted cell. Solamargine travels via the desmosomes to the lysosomes. The action of solamargine is lysosomotropic (rupturing of the lysosome). These events result in sudden cell death.
Read More

Topical treatment of pre-malignant and malignant skin cancers with Curaderm.
Drugs of Today, 1990

Curaderm, a topical preparation of a mixture of solasodine glycosides (BEC) which are present in some solanaceous plants, has become available to Australian practitioners for the treatment of cutaneous solar keratoses, basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs).
Read More